Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
177Lu-PSMA-617 beter dan cabazitaxel in fase II-studie
apr 2021 | Uro-oncologie